SCHEMBL289899

SCHEMBL289899

S=C(S)CCc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
CYP1A2 P05177 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP2C19 P33261 1/20 0.49
HRH3 Q9Y5N1 1/20 0.48
LMNA P02545 2/20 0.47
TAAR1 Q96RJ0 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18601247 0.91 CYP1A2 (0.57) HRH1CA12CA1CA2CA9
SCHEMBL2770164 0.89 HRH1 (0.54) HRH1CA12CA1CA2CA9
SCHEMBL4389586 0.84 HRH1 (0.53) HRH1CA12CA1CA2CA9
SCHEMBL2780427 0.82 SMN1; SMN2 (0.48) HRH1CA12CA1CA2CA9
SCHEMBL11354776 0.81 HRH1 (0.50) HRH1CA12CA1CA2CA9
SCHEMBL27477298 0.78 SMN1; SMN2 (0.56) HRH1CA12CA1CA2CA9
SCHEMBL11195301 0.78 HRH3 (0.51) HRH1CA12CA1CA2CA9
SCHEMBL29485678 0.78 HRH1 (0.73) HRH1CA12CA1CA2CA9
SCHEMBL230753 0.78 HRH1 (0.73) HRH1CA12CA1CA2CA9
SCHEMBL5669245 0.77 CYP1A2 (0.63) HRH1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-03-10 US claimed
EP-4684872-A1 DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-01-28 EP claimed
US-20230181466-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-06-15 US claimed
EP-4164693-A1 NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME Genentech, Inc. (US) 2023-04-19 EP claimed
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-02-09 US claimed
US-11446238-B2 Injectable dendrimer hydrogel nanoparticles WAYNE STATE UNIVERSITY (US) 2022-09-20 US claimed
EP-4054532-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-09-14 EP claimed
EP-4054533-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-09-14 EP claimed
WO-2021252803-A1 NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME GENENTECH, INC. (US) 2021-12-16 WO claimed
WO-2021152115-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-08-05 WO claimed
EP-1813614-B1 Cytotoxic agents comprising new tomaymycin derivatives SANOFI SA (FR) 2011-10-05 EP claimed
US-20100092567-A1 IMMUNOSTIMULATORY NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2010-04-15 US claimed
US-20090311276-A1 NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS LAWRENCE LIVERMORE NATIONAL SECURITY, LLC 2009-12-17 US claimed
WO-2009143280-A2 NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2009-11-26 WO claimed
EP-0550663-B1 MODIFIED ANTIBODIES WITH CONTROLLED CLEARANCE TIME TECHNICLONE INC (US) 1998-01-21 EP claimed
EP-0783894-A1 Antibodies modified at two separate sites TECHNICLONE, INC. (US) 1997-07-16 EP claimed
EP-0339264-B1 Compounds for the introduction of a mercapto group to tyrosin BOEHRINGER MANNHEIM GMBH (DE) 1994-08-03 EP claimed
EP-0252951-A4 TECHNETIUM-ANTIBODY CONJUGATE. UNIV MELBOURNE (AU) 1988-09-07 EP claimed
EP-0252951-A1 TECHNETIUM-ANTIBODY CONJUGATE THE UNIVERSITY OF MELBOURNE (AU) 1988-01-20 EP claimed
WO-1987004164-A1 TECHNETIUM-ANTIBODY CONJUGATE THE UNIVERSITY OF MELBOURNE (AU) 1987-07-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY PCNA, BOD1L1, SARS1 HRH1 4155/4885CA12 4005/4885CA1 4232/4885
US-11446238-B2 Injectable dendrimer hydrogel nanoparticles PAM, UACA, FLT1 HRH1 3255/4885CA12 3814/4885CA1 4603/4885
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles EXOSC10, PLTP, EXOSC9 HRH1 4356/4885CA12 2449/4885CA1 4488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.